|
Anacor is hardcore about curing skin conditions. The company is developing boron-based drug compounds for use as topical treatments of bacterial, fungal, and inflammatory conditions. Its lead candidate AN2690 aims to knock out a kind of toenail fungus; Anacor works with Merck to help develop and commercialize the drug. Other candidates in clinical and preclinical development include potential treatments for psoriasis, gingivitis, acne, yeast infections, and athlete's foot. Anacor has focused on topical treatments for the time being because they are relatively easy to develop and market, but it believes its boron chemistry can produce other kinds of drugs as well.
|
| | | Contact Information | |
Address: |
1060 E. Meadow Cir.
Palo Alto, CA 94303-4230
| | Phone: | 650-739-0700 | | Fax: | 650-739-0139 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 2.20 M | | Employees (2008): | 15 |
|
|
Key People
| | • |
Chairman:
Mark Leschly
| | • |
President, CEO, and Director:
David P. Perry
| | • |
SVP and CFO:
Christine E. Gray-Smith
|
|
|
